In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...

In the most recent data presented at the meeting, the CAR T-cell therapy demonstrated a 96 percent overall response rate.

At the meeting, researchers shared real-world data showing ctDNA positivity at the end of treatment was prognostic across lymphoma subtypes and better than PET scans.

One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that ...

The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients ...

In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.

The Phase III trial, testing the drug in patients whose cancers are Philadelphia chromosome-positive, will expand to the US and Europe.

The firm is developing Lumevoq as a treatment for Leber hereditary optic neuropathy caused by mutations in the ND4 mitochondrial gene.

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

AACR held an event on Capitol Hill with the NCI director and a legislator to discuss government efforts to support pediatric cancer research.

The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel ...

In the Phase I portion of the trial, there were no reported serious adverse events and a 100 percent complete response rate at the highest dose level of EB103.